Once you've made the decision to prescribe macitentan/tadalafil,


One Pill, One Fill1

As a single-tablet combination of an ERA and a PDE5 inhibitor, OPSYNVI® can help you to avoid the added time and complexity of 2 separate prescriptions, so that you can focus on patients, not paperwork1

No Added Cost

Patients will pay no more for OPSYNVI® than they would for OPSUMIT® (macitentan) when both drugs are covered on the same formulary tier, allowing them to forgo any out-of-pocket cost of a separate PDE5 inhibitor prescription


VOUCHER: A free trial offer is available for eligible patients to help them become familiar with OPSYNVI®. At the conclusion of the program, you and your patient decide whether to continue treatment. Subject to one (1) use per lifetime for the patient’s first trial of OPSYNVI®. Terms expire at the end of each calendar year and may change.

  • The program is open to patients who have commercial insurance, government coverage, or no insurance coverage; however, there is no guarantee of continuous accessibility after the program ends. See full program requirements at
Request a Medical
Science Liaison (MSL)Contact your MSL arrow

ERA=endothelin receptor antagonist; PDE5i=phosphodiesterase type 5 inhibitor.

Reference: 1. OPSYNVI® (macitentan/tadalafil) full Prescribing Information. Actelion Pharmaceuticals US, Inc.

Cookie Policy
No footer links content fetched